Telemetric Microsensor for Glaucoma

项目总结 青光眼是一种视神经疾病，视网膜神经节细胞进行性丧失导致 不可逆转的失明。据估计，它会影响2%的总人口。超过230万 美国人患有青光眼，据估计，青光眼造成了近30亿美元的直接医疗成本。 据估计，4%的高加索患者和8%的非裔美国患者将经历失明 由于青光眼。它是全球第二大致盲原因。 高眼压是最大的危险因素，也是唯一可改变的危险因素。 患有青光眼。测量眼压并将其降低到可减少视野损失进展的水平 神经退化是目前青光眼的治疗方法。典型的治疗方法包括眼压 在临床环境下用药物疗法测量自身给药的滴眼液，如噻吗洛尔和 拉坦前列素。在定期随访期间，眼压和眼睛健康被评估，药物治疗被调整为 在进一步的进展被阻止或减少之前是必要的。 可重复和准确的眼压测量是疾病管理的一个至关重要的因素。 高曼压平眼压计(GAT)是测量眼压的标准。的重大限制 GAT的特点是它提供间接眼压测量，并在单个时刻测量眼压。 然而，即使有这些限制，GAT仍然是测量眼压的黄金标准 青光眼的治疗。为了克服这一点，我们建议使用微型遥测压力。 用于连续、直接测量眼压的传感器装置。第一期可行性研究取得成功 为该项目继续进行到第二阶段提供了有利条件。 对于二期工程，我们提出了以下具体目标：(1)遥测压力的优化 传感器；(2)演示可穿戴式读取器单元以记录和显示压力测量结果；以及(3) 体内临床前研究的表现。

PROJECT SUMMARY Glaucoma is an optic nerve disease in which there is progressive loss of retinal ganglion cells leading to irreversible loss of vision. It is estimated to affect 2% of the general population. More than 2.3 million Americans are affected with glaucoma and it is estimated to account for nearly $3B in direct medical costs. It is estimated that 4% of Caucasian patients and 8% of African-American patients will experience blindness due to glaucoma. It is the second leading cause of blindness worldwide. High intraocular pressure (IOP) is the single largest, as well as the only modifiable, risk factor associated with glaucoma. Measuring and reducing IOP to levels that reduce the progression of visual field loss and nerve degradation is the current management approach for glaucoma. Typical treatment consists of IOP measurement in a clinical setting with a drug therapy of self-administered eye drops such as timolol and latanoprost. During periodic follow-ups, IOP and eye health is assessed and medication is adjusted as necessary until further progression is stopped or reduced. Reproducible and accurate IOP measurements are a critically important element of disease management. Goldman Applanation Tonometry (GAT) is the standard for measuring IOP. The significant limitations of GAT are that it provides an indirect IOP measurement and measures IOP at a single moment in time. However, even with these limitations, GAT has remained the gold standard for measuring IOP in the management of glaucoma. To overcome this, we propose the use of a micro-miniature, telemetric pressure sensor device for measuring IOP continuously and directly. The successful Phase I feasibility study provides merit for the continuation of the project into Phase II. For the Phase II project we propose the following Specific Aims: (1) Optimization of the telemetric pressure sensor; (2) Demonstration of a wearable reader unit to record and display pressure measurements; and (3) Performance of an in vivo preclinical study.